Our Story
Immediately,
accurately,
Easy to use.
BBB Inc. makes an ongoing, relentless effort in creativity.
Our mission at MARK-B™ platform is to change medical environment by providing affordable and accurate diagnostics in a compact platform designed for use in qualified labs.
OUR HISTORY
2014
Company Found
Oct. Founded headquarters in Korea
2016
Aug. Raised $5 million in 'Series A' round
2018
Mar. ‘MARK-B™ cancer’ Clinical testing and joint research with Seoul National University Bundang Hospital
Jul. Presented MARK-B™ Technology at AACC(American Association for Clinical Chemistry) in Chicago, USA
Oct. Raised 16.5 million in 'Series B'
2020
Jan.
'MARK-B™ CEA' test cartridge CE marked
Jun.
'MARK-B™ COVID-19 Ag S' CE marked,
‘Sampinute™ COVID-19 Antigen MIA’, CE marked
Aug.
KGMP Certificate acquisition
'MARK-B™ COVID-19 Ag S', the export certificate issued by MFDS
‘Sampinute™ COVID-19 Antigen MIA’, the export certificate issued by MFDS
OCT.
Sampinute™ COVID-19 MIA, FDA EUA approved
DEC.
ISO 13485:2016 Certificate acquisition
'MARK-B™ COVID-19 Ag’, CE marked
2015
Jan. Joined HAX Batch 6 program
Apr. Signed OEM contract with GreenCross MS for supply of in-vitro diagnostic devices for hospitals
May. Tech-In-Asia Award Winner <beGlobal Seoul 2015>
Oct. Winner of Zhongguancun Innoway <2015 Demo The World> in Smart Hardware Sector
2017
Apr. Signed OEM contract with Philosys Inc. for supply of glucosmeters for hospital use
Jun. Signed MOU with Busan University to commercialize medical research and infrastructure
Jun. Signed MOU with Korea University Guro Hospital to develop next-generation immunodiagnostic kit for cancer, myocardial infarction, and chronic disease
Aug. Signed OEM contract with GenBody Inc. for supply of rapid test readers for arboviruses and drugs of abuse
Nov. Launched elemark® dual check in Korea
2019
Mar. Completed a Joint “Cancer Diagnostic Performance Verification Clinical Trial” with Seoul National University Bundang Hospital
Aug. Launched elemark® dual check 2 in Korea
2021
Jan.
'MARK-B™ COVID-19 Ag', the export certificate issued by MFDS
Aug.
'MARK-B™ COVID-19 Ag', approved by MFDS
'MARK-B™ COVID-19 Ag', certified the Excellent R&D Innovation Product Award by KIPO
Sep.
'MARK-B™ COVID-19 Ag', completed validation by AFMPS
RECENT PUBLICATIONS
Clinical Laboratory
August, 2019
“Evaluation of MARK-B™ for Quantitative Measurement of Three Tumor Markers:
Prostate Specific Antigen, Alpha Fetoprotein, and Carcinoembryonic Antigen”
Tumor marker assays have played a crucial role for screening cancers and monitoring cancer patients, as they reflect the status and prognosis of patients. Alpha fetoprotein (AFP), prostate specific antigen (PSA), and carcinoembryonic antigen (CEA) are the most commonly used tumor marker proteins. The MARK B™ immunoassay system is a novel platform based on magnetic nanoparticles and electrochemical immunoassay. read
Analytica Chimica Acta
March, 2019
“MESIA: Magnetic force-assisted electrochemical sandwich immunoassays
for quantification of prostate-specific antigen in human serum”
We propose a new immunoassay technique, called magnetic-force assisted electrochemical sandwich immunoassay (MESIA), where serum biomarkers can be determined by magnetic actuation and electrochemical detection of gold-coated iron oxide nanoparticles as probes for immunocomplex formation. In MESIA, neither washing buffer nor fluidic parts are necessary, because the formation of immunocomplexes and the removal of unbound probes are controlled by magnetic forces. read
Biosensors and Bioelectronics
July, 2018
“Magnetic force assisted electrochemical sensor for the detection of thrombin
with aptamer-antibody sandwich formation”
A magnetic force assisted electrochemical aptamer-antibody sandwich assay(MESA) was developed for the detection of thrombin as a model protein in serum samples. The MESA using the formation of sandwich complexes on the electrochemical sensor probe for reaction and the removal of unbound bioconjugates from the sensor surface without washing are controlled by a magnetic field. read
